Trials / Completed
CompletedNCT04214028
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
Real World Evidence of the Safety and Clinical Practice Use of Maviret in Adolescents Patients Infected With Chronic Hepatitis C Virus (All Case Survey)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.
Conditions
Timeline
- Start date
- 2019-12-26
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
- First posted
- 2019-12-30
- Last updated
- 2025-07-20
Locations
54 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04214028. Inclusion in this directory is not an endorsement.